SCHEMBL21724124

SCHEMBL21724124

COCCn1cc(C(=O)Cl)c(OC)n1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAP3K5 Q99683 6/20 0.44
▸ KMT2A Q03164 2/20 0.34
▸ IRAK4 Q9NWZ3 3/20 0.34
▸ IKBKB O14920 1/20 0.33
▸ MAP4K4 O95819 1/20 0.33
▸ EGFR P00533 1/20 0.33
▸ FRK P42685 1/20 0.33
▸ MAPK9 P45984 1/20 0.33
▸ CSNK1D P48730 1/20 0.33
▸ SLK Q9H2G2 1/20 0.33
▸ CNR1 P21554 2/20 0.33
▸ CNR2 P34972 2/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ IKBKE Q14164 1/20 0.31
▸ TBK1 Q9UHD2 1/20 0.31
▸ LRRK2 Q5S007 1/20 0.31
▸ NR3C1 P04150 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21723855 0.86 MAP3K5 (0.45) MAP3K5KMT2AIKBKB
SCHEMBL21724143 0.81 MAP3K5 (0.45) MAP3K5KDM4E
SCHEMBL1657677 0.80 KMT2A (0.40) MAP3K5KMT2A
SCHEMBL25184413 0.75 AADAT (0.47) KMT2AL3MBTL1
SCHEMBL20524617 0.71 KMT2A (0.42) MAP3K5KMT2AL3MBTL1KDM4E
SCHEMBL2078208 0.71 IKBKB (0.41) MAP3K5IRAK4IKBKBIKBKETBK1
SCHEMBL26141144 0.70 MAP3K5 (0.38) MAP3K5MAP4K4EGFRFRKMAPK9
SCHEMBL29002512 0.70 KMT2A (0.36) MAP3K5KMT2AIRAK4KDM4E
SCHEMBL20524696 0.70 NR4A2 (0.38) MAP3K5KMT2AL3MBTL1
SCHEMBL28637007 0.69 L3MBTL1 (0.49) MAP3K5L3MBTL1IKBKETBK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11999715-B2 ASK1 inhibiting agents BIOGEN MA INC. (US) 2024-06-04 — — US disclosed
EP-3837251-B1 ASK1 INHIBITING AGENTS BIOGEN MA INC (US) 2023-06-21 — — EP disclosed
EP-3837251-B1 ASK1 INHIBITING AGENTS BIOGEN MA INC (US) 2023-06-21 — — EP disclosed
US-20210317103-A1 ASK1 INHIBITING AGENTS BIOGEN MA INC. 2021-10-14 — — US disclosed
US-20210317103-A1 ASK1 INHIBITING AGENTS BIOGEN MA INC. 2021-10-14 — — US disclosed
CN-113227070-A ASK1 inhibitors 比奥根MA公司 2021-08-06 — — CN disclosed
EP-3837251-A1 ASK1 INHIBITING AGENTS Biogen MA Inc. (US) 2021-06-23 — — EP disclosed
WO-2020036949-A1 ASK1 INHIBITING AGENTS BIOGEN MA INC. (US) 2020-02-20 — — WO disclosed
WO-2020036949-A1 ASK1 INHIBITING AGENTS BIOGEN MA INC. (US) 2020-02-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317103-A1 ASK1 INHIBITING AGENTS MAP3K1, MAP3K6, MAP3K10 MAP3K5 10/4885KMT2A 3569/4885IRAK4 32/4885
US-11999715-B2 ASK1 inhibiting agents MAP3K1, MAP3K6, MAP3K10 MAP3K5 10/4885KMT2A 3569/4885IRAK4 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback